H. Lundbeck A/S (Lundbeck) today announced plans to restructure its
commercial organisation in Europe. The aim is partly to establish a more
flexible commercial infrastructure with respect to detailing to general
practitioners ahead of multiple future product launches and partly to maintain
cost control. The plan is to uphold Lundbeck's position as a leading CNS
specialist and secure successful launches of new products.
The proposed
restructuring is intended to pave the way for a successful transition of
Lundbeck's European product portfolio with several potential product launches
in the coming years. Furthermore, the initiative aims to mitigate increased
pressure from healthcare reforms, generic competition and uncertainty regarding
pricing and reimbursement in Europe.
"The market environment in Europe is changing rapidly at a time when
Lundbeck has numerous new products to launch. To ensure a successful transition
of our product portfolio in Europe we need a more flexible commercial
infrastructure and to maintain cost control," says Ulf Wiinberg, President
and CEO of Lundbeck.
Lundbeck continues to invest in growth markets
This project is expected to involve the reduction of around 600 positions in our subsidiaries primarily in Europe. Lundbeck will continue with the current plans for investments in markets of growth comprising the US and International Markets.
Lundbeck cares for employees who may be laid off. We will do our utmost to
manage the process in a respectful way and will now initiate a consultation
process regarding the anticipated staff reductions with the works councils in
the most affected markets. Lundbeck has informed the company's European Works Council about the
restructuring plans.